Regeneron Pharmaceuticals, Inc. (REGN) 2024 10-K Earnings Analysis
Regeneron Pharmaceuticals, Inc.2024 Earnings Analysis
80/100
Regeneron's FY2024 10-K shows $14.2B revenue, $4.4B net income, 28.1% operating margin, and $3.7B free cash flow — driven by the Eylea/Eylea HD ophthalmology franchise plus the Sanofi-partnered Dupixent revenue (collaboration revenue and profit share per the partnership disclosures). Zero goodwill confirms organic R&D-driven growth. Founders Leonard Schleifer (CEO since 1988) and George Yancopoulos (President and Chief Scientific Officer) lead the company per the FY2024 proxy.
Filing analysis
Regeneron Pharmaceuticals, Inc. 2024 10-K Analysis
This page reads Regeneron Pharmaceuticals, Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 80/100, or grade B.
REGN Earnings Quality
The earnings-quality module scores 86/100, with Operating Margin: 28.1%, CF/Net Income: 1.00x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
REGN Economic Moat Analysis
The moat-strength module scores 86/100, with Eylea HD Lifecycle: 8mg high-dose, Dupixent Co-Development: Multi-indication. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
REGN Free Cash Flow vs Net Income
CF/Net Income: 1.00x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 80/100. For the diagnostic, start with cash flow vs net income.
REGN Key Risks from the Annual Report
The risk module scores 68/100, with Eylea Biosimilar Entry: 2024 onward, Dupixent Patent Horizon: Multi-year. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is REGN a High Quality Earnings Stock?
Based on this 2024 filing, REGN passes the first screen for high-quality earnings: the overall grade is B, and the earnings-quality score is 86/100. This is a research screen, not investment advice.
Read the report first
Understand Regeneron Pharmaceuticals, Inc. first, then decide if it belongs on your watchlist
The REGN score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep REGN with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the REGN report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, operating margin of 28.1% reflects the branded-biotech operating model — Eylea and Eylea HD ophthalmology revenue plus the Sanofi-collaboration profit-share-and-collaboration revenue from Dupixent and Libtayo per the collaboration footnote.
Per the FY2024 cash flow statement, OCF of $4.4B is approximately 1.00x net income of $4.4B — a tight conversion reflecting limited non-cash distortion. Stock-based compensation and standard depreciation are the principal non-cash items per the cash-flow reconciliation.
Per the FY2024 product-revenue disclosures, Eylea (aflibercept) and Eylea HD (the higher-dose 8mg formulation FDA-approved in August 2023 per the regulatory press release) treat wet AMD, diabetic macular edema, and other retinal conditions. Eylea HD launch dynamics are the principal franchise-trajectory signal per MD&A.
Per the FY2024 collaboration-revenue footnote, Regeneron's Sanofi partnership covers Dupixent (atopic dermatitis, asthma, eosinophilic esophagitis, prurigo nodularis, COPD per the FDA-approved labels) and historically Libtayo (now wholly-owned by Regeneron per the 2022 Sanofi-restructuring disclosure). The Sanofi-partnered profit share is a principal earnings contributor.
Earnings quality scores 86/100. Per the FY2024 10-K, Regeneron's $14.2B revenue produces a 28.1% operating margin and 1.00x CF/NI ratio — clean biotech earnings economics. The Eylea/Eylea HD ophthalmology franchise plus the Sanofi-collaboration profit share from Dupixent shape the revenue composition disclosed in the collaboration footnote.
Moat Strength
Per the August 2023 FDA-approval press release for Eylea HD (aflibercept 8mg) and the FY2024 ophthalmology-franchise MD&A, the higher-dose 8mg formulation supports Eylea franchise lifecycle extension via reduced injection frequency. Conversion progress is disclosed in quarterly franchise communications.
Per Sanofi's and Regeneron's joint product-disclosure communications, Dupixent (dupilumab) has expanded across multiple atopic-and-inflammatory indications via successive FDA-approval announcements — atopic dermatitis, asthma, EoE, prurigo nodularis, and COPD. The multi-indication-expansion trajectory is a structural-revenue-growth lever for the Sanofi-Regeneron collaboration.
Per the FY2024 10-K R&D-pipeline section and ClinicalTrials.gov-registered programs, Regeneron's pipeline includes oncology bispecifics (Lynozyfic now-Linvoseltamab and others), Itepekimab (COPD with Sanofi), genetic-therapy collaborations, and additional candidates. Multi-program pipeline depth supports the long-cycle R&D-driven thesis.
Per the FY2024 balance sheet, goodwill is effectively zero — Regeneron has grown principally through internal R&D rather than acquisition-driven scaling. No M&A-driven impairment exposure.
Moat strength scores 86/100. Per the FY2024 10-K, Regeneron's competitive position rests on (1) the Eylea/Eylea HD ophthalmology franchise with the August 2023 FDA-approved 8mg lifecycle extension per the regulatory press release, (2) the Sanofi-partnered Dupixent franchise with disclosed multi-indication FDA approvals (atopic dermatitis, asthma, EoE, prurigo nodularis, COPD), (3) the in-house R&D pipeline depth disclosed via ClinicalTrials.gov registry, and (4) the zero-goodwill organic-growth posture.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $3.7B (OCF $4.4B minus capex $0.76B) supports the share-repurchase program plus continued R&D reinvestment.
Per the FY2024 R&D-spending disclosure, Regeneron continues to allocate a meaningful share of revenue to internal research — the disclosed R&D-to-revenue ratio is among the higher ranges in the biotech peer set per publicly-comparable filings.
Per the FY2024 capital-return disclosures, Regeneron operates an active share-repurchase program. No regular dividend is paid per the capital-allocation section.
Per Regeneron's 2022 Sanofi-restructuring disclosures, the partnership was restructured to give Regeneron full Libtayo rights and modify the IL-33 (Itepekimab) collaboration economics. The restructured collaboration profile is reflected in the FY2024 collaboration revenue footnote.
Capital allocation scores 80/100. Per the FY2024 10-K, $3.7B FCF supports active share-repurchase activity per the capital-return disclosure plus continued R&D reinvestment at a level among the higher biotech peer ranges per publicly-comparable filings. No regular dividend is paid. The 2022 Sanofi-collaboration restructuring per the company's disclosure adjusted the long-run economics across Libtayo and IL-33 programs.
Key Risks
Per the FY2024 Risk Factors and FDA biosimilar-approval disclosures, Eylea (aflibercept) faces biosimilar competition with multiple biosimilar candidates approved or under FDA review (including Yesafili approved per the 2024 FDA disclosure plus competitor candidates). Conversion to Eylea HD per the 8mg-formulation patent protection is the disclosed lifecycle-defense strategy.
Per the FY2024 Risk Factors and Dupixent-related patent disclosures, Dupixent's principal patent protection extends across the multi-year horizon disclosed in successive 10-Ks. The Sanofi-Regeneron collaboration economics depend on the patent-protection runway.
Per the FY2024 Risk Factors, successful pipeline execution depends on clinical-trial readouts (oncology bispecifics, COPD Itepekimab, genetic-therapy collaborations) tracked via ClinicalTrials.gov and company press releases.
Per HHS CMS public communications under the Inflation Reduction Act, Medicare drug-price-negotiation selection rounds will progress over multi-year periods. Eylea has been selected on a 2025 negotiation round per the CMS public disclosure — the resulting price impact applies in subsequent program years.
Risk profile scores 68/100 (higher = safer). Per the FY2024 10-K, the principal watch-items are (1) Eylea biosimilar entry per FDA biosimilar-approval disclosures with Yesafili and other candidates — Eylea HD lifecycle defense strategy is the response, (2) Dupixent's multi-year patent-protection horizon per the Risk Factors, (3) pipeline-execution risk on oncology bispecifics, IL-33 (Itepekimab COPD), and genetic-therapy programs per ClinicalTrials.gov and company press releases, and (4) Eylea Medicare IRA drug-price-negotiation exposure per CMS public disclosures.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.